68M with atrial fibrillation for pre-op evaluation
A 68-year-old man with a history of nonvalvular atrial fibrillation, hypertension, type 2 diabetes, and an ischemic stroke three years ago presents for preoperative evaluation. He is scheduled for an elective laparoscopic inguinal hernia repair in two weeks. He is a retired accountant and is eager to have the procedure to resume playing golf. His medications include apixaban 5 mg twice daily, lisinopril, and metformin. He has no history of bleeding or thromboembolism while on apixaban. His estimated creatinine clearance is 45 mL/min. On examination, vital signs are normal and the physical examination is unremarkable except for a reducible right inguinal hernia. Which of the following is the most appropriate recommendation for his perioperative anticoagulation management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
C
Explanation
Clinical Pearl:
For patients on direct oral anticoagulants (DOACs) undergoing procedures with low-to-moderate bleeding risk, bridging anticoagulation is generally not recommended, regardless of the baseline thromboembolic risk. The interruption period for the DOAC is based on the specific agent, renal function, and procedural bleeding risk.
Explanation:
This patient has a high thromboembolic risk (CHA2DS2-VASc score of 5) and requires perioperative management of apixaban for a procedure with low-to-moderate bleeding risk. The most appropriate management is to stop apixaban 48 hours before the procedure and resume postoperatively without bridging. According to current cardiology society guidelines, routine bridging anticoagulation for patients on DOACs is not recommended as it increases bleeding risk without a clear benefit in reducing thromboembolic events. A 48-hour hold is appropriate for apixaban before a procedure with low-to-moderate bleeding risk, especially with a creatinine clearance below 50 mL/min. Continuing apixaban is incorrect because laparoscopic inguinal hernia repair carries a non-minimal risk of bleeding. Bridging with therapeutic-dose enoxaparin is not indicated and increases bleeding risk. Bridging with prophylactic-dose enoxaparin is also incorrect as bridging is not needed and a prophylactic dose is insufficient for stroke prevention in high-risk atrial fibrillation. Stopping apixaban only 24 hours prior is an insufficient duration given the procedural risk and the patient's reduced renal function.
See you tomorrow morning!